Similar Natural Products in NPASS
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC319114 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 6984 |
0.1-0.2 | 19358 |
0.2-0.3 | 3431 |
0.3-0.4 | 717 |
0.4-0.5 | 316 |
0.5-0.6 | 70 |
0.6-0.7 | 8 |
0.7-0.8 | 4 |
0.8-0.85 | 0 |
0.85-0.9 | 0 |
0.9-0.95 | 0 |
0.95-1 | 1 |
  Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC319114 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 284 |
0.1-0.2 | 5295 |
0.2-0.3 | 2749 |
0.3-0.4 | 533 |
0.4-0.5 | 240 |
0.5-0.6 | 44 |
0.6-0.7 | 12 |
0.7-0.8 | 3 |
0.8-0.85 | 1 |
0.85-0.9 | 0 |
0.9-0.95 | 0 |
0.95-1 | 0 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8095 |
Intermediate Similarity |
NPD9227 |
Discontinued |
0.7368 |
Intermediate Similarity |
NPD401 |
Approved |
0.7179 |
Intermediate Similarity |
NPD1156 |
Clinical (unspecified phase) |
0.7021 |
Intermediate Similarity |
NPD1154 |
Phase 3 |
0.6607 |
Remote Similarity |
NPD1155 |
Discontinued |
0.6591 |
Remote Similarity |
NPD2707 |
Clinical (unspecified phase) |
0.6585 |
Remote Similarity |
NPD2276 |
Clinical (unspecified phase) |
0.65 |
Remote Similarity |
NPD8613 |
Approved |
0.6458 |
Remote Similarity |
NPD397 |
Phase 2 |
0.6304 |
Remote Similarity |
NPD2273 |
Clinical (unspecified phase) |
0.62 |
Remote Similarity |
NPD399 |
Approved |
0.62 |
Remote Similarity |
NPD398 |
Approved |
0.62 |
Remote Similarity |
NPD400 |
Approved |
0.6066 |
Remote Similarity |
NPD2703 |
Discontinued |
0.6032 |
Remote Similarity |
NPD3213 |
Discontinued |
0.6 |
Remote Similarity |
NPD9465 |
Approved |
0.5957 |
Remote Similarity |
NPD1463 |
Clinical (unspecified phase) |
0.5902 |
Remote Similarity |
NPD6438 |
Approved |
0.5902 |
Remote Similarity |
NPD6437 |
Approved |
0.575 |
Remote Similarity |
NPD9063 |
Approved |
0.575 |
Remote Similarity |
NPD9064 |
Approved |
0.5741 |
Remote Similarity |
NPD8815 |
Suspended |
0.5714 |
Remote Similarity |
NPD9458 |
Approved |
0.5692 |
Remote Similarity |
NPD2704 |
Phase 3 |
0.5692 |
Remote Similarity |
NPD2702 |
Phase 1 |
0.5682 |
Remote Similarity |
NPD8556 |
Phase 3 |
0.5652 |
Remote Similarity |
NPD9059 |
Approved |
0.5606
|
Remote Similarity |
NPD5386 |
Phase 2 |